Hasil Pencarian - Urban Emmenegger

  • Menampilkan 1 - 10 hasil dari 10
Perbaiki Hasil
  1. 1
    Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer

    Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer oleh Juan Briones, Maira Khan, Amanjot K. Sidhu, Liying Zhang, Martin Smoragiewicz, Martin Smoragiewicz, Urban Emmenegger, Urban Emmenegger, Urban Emmenegger, Urban Emmenegger

    Diterbitkan 2021-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide

    Tumors That Acquire Resistance to Low-Dose Metronomic Cyclophosphamide Retain Sensitivity to Maximum Tolerated Dose Cyclophosphamide oleh Urban Emmenegger, Giulio Francia, Annabelle Chow, Yuval Shaked, Andrew Kouri, Shan Man, Robert S. Kerbel

    Diterbitkan 2011-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy

    Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy oleh Terence C. Tang, Shan Man, Ping Xu, Giulio Francia, Kae Hashimoto, Urban Emmenegger, Robert S. Kerbel

    Diterbitkan 2010-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial

    Prostate MRI versus PSA screening for prostate cancer detection (the MVP Study): a randomised clinical trial oleh Urban Emmenegger, Chirag Patel, Christopher Wallis, Amanda Hird, Christopher Sherman, Robert Nam, Laurent Milot, Patrick Macinnis, Mala Singh, Masoom A Haider

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer.

    The impact of sarcopenia on clinical outcomes in men with metastatic castrate-resistant prostate cancer. oleh Efthymios Papadopoulos, Andy Kin On Wong, Sharon Hiu Ching Law, Lindsey Ze Jing Zhang, Henriette Breunis, Urban Emmenegger, Shabbir M H Alibhai

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer

    Targeting PLOD2 suppresses invasion and metastatic potential in radiorecurrent prostate cancer oleh Gavin Frame, Hon Leong, Roni Haas, Xiaoyong Huang, Jessica Wright, Urban Emmenegger, Michelle Downes, Paul C. Boutros, Thomas Kislinger, Stanley K. Liu

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice

    <sup>177</sup>Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice oleh Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad

    Diterbitkan 2024-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS)

    Future directions for bone metastasis research – highlights from the 2015 bone and the Oncologist new updates conference (BONUS) oleh Ricardo Fernandes, Peter Siegel, Svetlana Komarova, John Hilton, Christina Addison, Mohammed F K Ibrahim, Joel Werier, Kristopher Dennis, Gurmit Singh, Eitan Amir, Virginia Jarvis, Urban Emmenegger, Sasha Mazzarello, Mark Clemons

    Diterbitkan 2016-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up

    347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of... oleh Urban Emmenegger, Howard Gurney, Emanuela Romano, Neal Shore, Margitta Retz, Christian Poehlein, Charles Schloss, Leonard Appleman, Gwenaelle Gravis, Loïc Mourey, Josep Piulats, Evan Yu, Johann De Bono, William Berry, Peter Fong, Cristiano Ferrario, Tilman Todenhoefer, Henry Conter, Brigitte Laguerre, Xin Tong Li

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC)

    351 KEYNOTE-365 cohort D: pembrolizumab plus abiraterone acetate and prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) oleh Urban Emmenegger, Christian Poehlein, Charles Schloss, Leonard Appleman, Loïc Mourey, Anthony Joshua, Mark Linch, Josep Piulats, Evan Yu, Johann De Bono, William Berry, Peter Fong, Cristiano Ferrario, Tilman Todenhoefer, Henry Conter, Brigitte Laguerre, Xin Tong Li, Michael Stoeckle, Jose Arranz, Nataliya Mar

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: